Our results show that, even after the exclusion of underweight patients from the sample, SIRT1 maintained a positive role in regulating TBS, the bone structure most exposed to the effects of metabolic disorder, and sclerostin has a negative impact on BMD. This evidence concerns the gene SIRT1 and Other metabolic disease.